Tarlatamab Shows Promise in Tackling Previously Treated SCLC

The investigational drug led to encouraging overall survival and intracranial disease control in patients with small-cell lung cancer, longer-term trial data suggested.

Related Keywords

London ,City Of ,United Kingdom ,Mainfranken ,Bayern ,Germany ,Italy ,Horst Dieter Hummel ,Tom Newsom Davis ,Cancer Center Mainfranken ,European Lung Cancer Congress ,Comprehensive Cancer Center Mainfranken ,Jessica Menis ,Oncology Department ,University Hospital ,Westminster Hospital ,